Project demonstrates that a multiplex tNGS assay can function as a reliable and informative diagnostic tool.
We are at a critical crossroads for the clinical use of ctDNA in early-stage breast cancer, according to Dr. Heather A. Parsons. “What if we could reliably identify molecular re ...
The Tallahassee Democrat revisited Florida State University researchers to talk about seafood mislabeling happening in the ...
Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first ...
Doctors address the pros and cons of Health Resources and Services Administration’s new guidance, including at-home ...
The COVID-19 pandemic brought the term "Polymerase Chain Reaction testing" into the mainstream. The PCR method is a type of ...
Anbio Biotechnology continues pivoting toward better profitability metrics, prioritized high-margin orders over sales volume. Read more on NNNN stock here.
This GEN eBook examines how ddPCR technology is applied in practice through case studies highlighting its analytical strengths over traditional qPCR.
NEW YORK – Hepion Pharmaceuticals has acquired the rights to develop Cirna Diagnostics' circulating tumor RNA (ctRNA) biomarker assay that can detect early, high-risk hepatocellular carcinoma, the ...
Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a precision diagnostics company, today announced that it has in-licensed from ...
The FDA has cleared a multiplex polymerase chain reaction test designed to detect 11 clinically relevant gastrointestinal pathogens from a single stool sample.The Xpert GI Panel (Cepheid) can identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results